MedTrace Logo

SkIN hydrAtion Evaluation With TeRAhertz Scanning

NCT05121207 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 79

Last updated 2024-06-20

No results posted yet for this study

Summary

Medical imaging commonly involves the use of radiation, such as x-rays, that can give detailed images of internal structures of the body but can carry a small risk of tissue damage due to the radiation involved. As such, the number of x-rays and computed tomography (CT) scans that an individual can have has to be minimised. Methods have recently been developed that make use of electromagnetic radiation for imaging purposes at terahertz (THz) frequencies, the region of the spectrum between millimetre wavelengths and infrared. Terahertz spectroscopic imaging uses low power levels such that adverse effects on tissues are insignificant and is safe for in vivo imaging of humans \[1\]. The terahertz region is between the radio frequency region and the optical region generally associated with lasers. Both the IEEE RF safety standard and the ANSI Laser safety standard have limits into the terahertz region. The focus of this project is to investigate THz spectroscopic imaging as a new and powerful tool for analysing skin properties, termed "THz skinometry". The novelty in this project lies in tailoring the instrumentation and algorithms of THz scanning to accurately measure properties of human skin (e.g. hydration levels and skin thickness) in vivo. The customised non-contact and pressure-controlled contact THz probes developed will be able to do spectroscopic measurements of skin in vivo at the molecular level. This will be the first demonstration of in vivo THz imaging of skin globally and will facilitate quantitative characterisation of skin in a way that has hitherto not been possible and could lead to a step change in THz technology usage (similar to that currently used in airport security scanners).

Conditions

Interventions

DEVICE

Terahertz scanning

Short scans using Terahertz device

Sponsors & Collaborators

  • University of Warwick

    collaborator OTHER

  • University Hospitals Coventry and Warwickshire NHS Trust

    lead OTHER

Study Design

Allocation
NON_RANDOMIZED
Purpose
DIAGNOSTIC
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
100 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-02-28
Primary Completion
2023-03-15
Completion
2023-03-15

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05121207 on ClinicalTrials.gov